Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 1998

View Archived Issues

Pramipexole improves rest tremor in Parkinson's disease

Anika receives nonapprovable letter from FDA for Orthovisc

Ramoplanin enters phase II trials in U.S. for eliminating VREF from intestine

Cell Therapeutics initiates phase I lisofylline trial for treatment of mucositis

Phase II study of BB-10010 for maintaining hematopoiesis in patients undergoing chemotherapy

Coulter announces positive investigational phase III results from Bexxar in NHL

Japanese patent allowed for Maxamine technology

Amylin announces positive phase I trial results for diabetes compound

NOS inhibitors developed at Chugai reportedly useful for cerebrovascular disorders

DuPont discloses heteroaromatic factor Xa inhibitors

Dopaminergic and serotonergic agents synthesized at Lundbeck

New antiplatelet agents in the pipeline at Astra

Astra patents novel immunosuppressive agents

Toyama licenses neuroprotective compound from Senju

Lomerizine, a new antimigraine agent, compared to flunarizine in rats

Elevated levels of homocysteine a potential risk factor in AD

Animal studies with KW-6002, a novel therapeutic for PD, presented at international congress

SIB-1508Y exerts neuroprotective effects in addition to beneficial motor/cognitive actions

Weight-loss drugs: some disappoint, others look more promising

Delta-opioid agonists considered to have potential for improving PD symptoms

Lilly studies antiinfluenza virus drug candidate with a unique mechanism of action

NHE inhibitor BIIB-513 protects against ischemia/reperfusion injury in dogs

New treatment for AD now marketed in Germany

Tacrolimus in the long-term treatment of atopic dermatitis

Ondansetron effective and safe in controlling TD and psychotic symptoms

Role of neuromelanin in neuronal damage

Fexofenadine in the treatment of chronic idiopathic urticaria

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 13, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...